These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29484139)

  • 1. S100A9
    Feng PH; Yu CT; Chen KY; Luo CS; Wu SM; Liu CY; Kuo LW; Chan YF; Chen TT; Chang CC; Lee CN; Chuang HC; Lin CF; Han CL; Lee WH; Lee KY
    Oncotarget; 2018 Jan; 9(7):7631-7643. PubMed ID: 29484139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma.
    Feng PH; Chen KY; Huang YC; Luo CS; Wu SM; Chen TT; Lee CN; Yeh CT; Chuang HC; Han CL; Lin CF; Lee WH; Kuo CH; Lee KY
    J Thorac Oncol; 2018 Jul; 13(7):958-967. PubMed ID: 29684573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 4. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer.
    Feng PH; Lee KY; Chang YL; Chan YF; Kuo LW; Lin TY; Chung FT; Kuo CS; Yu CT; Lin SM; Wang CH; Chou CL; Huang CD; Kuo HP
    Am J Respir Crit Care Med; 2012 Nov; 186(10):1025-36. PubMed ID: 22955317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction: S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB.
    Feng PH; Yu CT; Chen KY; Luo CS; Wu SM; Liu CY; Kuo LW; Chan YF; Chen TT; Chang CC; Lee CN; Chuang HC; Lin CF; Han CL; Lee WH; Lee KY
    Oncotarget; 2018 Jul; 9(59):31559. PubMed ID: 30140390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer.
    Chung FT; Lee KY; Wang CW; Heh CC; Chan YF; Chen HW; Kuo CH; Feng PH; Lin TY; Wang CH; Chou CL; Chen HC; Lin SM; Kuo HP
    Int J Cancer; 2012 Aug; 131(3):E227-35. PubMed ID: 22174092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
    Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM
    Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma.
    Zhang B; Zhang Y; Zhao J; Wang Z; Wu T; Ou W; Wang J; Yang B; Zhao Y; Rao Z; Gao J
    Med Oncol; 2014 Aug; 31(8):127. PubMed ID: 25034365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
    Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer.
    de Goeje PL; Bezemer K; Heuvers ME; Dingemans AC; Groen HJ; Smit EF; Hoogsteden HC; Hendriks RW; Aerts JG; Hegmans JP
    Oncoimmunology; 2015 Jul; 4(7):e1014242. PubMed ID: 26140237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
    Zhang X; Maity T; Kashyap MK; Bansal M; Venugopalan A; Singh S; Awasthi S; Marimuthu A; Charles Jacob HK; Belkina N; Pitts S; Cultraro CM; Gao S; Kirkali G; Biswas R; Chaerkady R; Califano A; Pandey A; Guha U
    Mol Cell Proteomics; 2017 May; 16(5):891-910. PubMed ID: 28331001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-associated macrophage-derived exosomes promote EGFR-TKI resistance in non-small cell lung cancer by regulating the AKT, ERK1/2 and STAT3 signaling pathways.
    Yuan S; Chen W; Yang J; Zheng Y; Ye W; Xie H; Dong L; Xie J
    Oncol Lett; 2022 Oct; 24(4):356. PubMed ID: 36168315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting 14-3-3ζ Overcomes Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma via BMP2/Smad/ID1 Signaling.
    Cui J; Song Y; Han X; Hu J; Chen Y; Chen X; Xu X; Xing Y; Lu H; Cai L
    Front Oncol; 2020; 10():542007. PubMed ID: 33123465
    [No Abstract]   [Full Text] [Related]  

  • 15. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
    Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
    Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
    Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
    J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma.
    Kim HR; Cho BC; Shim HS; Lim SM; Kim SK; Chang J; Kim DJ; Kim JH
    Lung Cancer; 2014 Mar; 83(3):374-82. PubMed ID: 24468202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optical in vivo imaging of the alarmin S100A9 in tumor lesions allows for estimation of the individual malignant potential by evaluation of tumor-host cell interaction.
    Becker A; Große Hokamp N; Zenker S; Flores-Borja F; Barzcyk K; Varga G; Roth J; Geyer C; Heindel W; Bremer C; Vogl T; Eisenblaetter M
    J Nucl Med; 2015 Mar; 56(3):450-6. PubMed ID: 25678492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
    Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS
    Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.